Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 19, 2026Clinical Cancer Research

Abstract PS1-10-20: Free-her: discontinuation of maintenance her-2 directed therapy in long-term survivors of metastatic her-2 positive breast cancer: a trial update

View Full Paper
Ask AI
Bookmark
Share

Authors

EJE. Krill JacksonSylvester Comprehensive Cancer CenterFVF. valdesSylvester Comprehensive Cancer CenterCCC. CalfaUniversity of Miami

Discussion

Loading...

Member takes

Implication

Pilot study evaluates the safe discontinuation of HER-2 therapy in long-term survivors of metastatic breast cancer, suggesting potential for less treatment burden.

Key Points

  • This study aims to determine if discontinuing HER-2 directed therapy is feasible for patients with long-term complete remission of metastatic HER-2 positive breast cancer.
  • Single-site pilot study with IRB approval
  • Enrolled 20 patients with stage IV HER-2 positive breast cancer in CRR for at least 36 months
  • Patients monitored through ctDNA testing at intervals after treatment discontinuation
  • 14 patients enrolled with a median age of 64.5 years
  • Only 2 patients developed positive ctDNA post-discontinuation, indicating potential safety of therapy cessation
  • No deaths occurred during the trial, with a maximum follow-up of 24 months

Cite This Study

Jackson et al. (2026) studied this question.

synapsesocial.com/papers/6996a84cecb39a600b3eee8bhttps://doi.org/10.1158/1557-3265.sabcs25-ps1-10-20
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase II study evaluating treatment discontinuation of dual anti-HER2 therapy in metastatic HER2-positive breast cancer after five years of sustained complete response (FREEDOME-trial).2026
  2. 2Abstract PO2-20-01: The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+ Metastatic Breast Cancer (TBCRC 062)2024 · 4 citations
  3. 3Abstract PS5-02-14: "longterm" - long-term response (>18 months) in metastatic her2-positive breast cancer: a retrospective analysis of patients diagnosed between 2010 and 2020 in the german bngo network2026
  4. 4Abstract PS3-10-18: Early Discontinuation of Adjuvant Endocrine Therapy in Patients with Triple Positive Early Stage Breast Cancer after Pathologic Complete Response (pCR) to Neoadjuvant Therapy: A Retrospective Review2026
  5. 5Treatment of HER2 positive stage 4 breast cancer: When to stop anti-HER2 agents.2024